The American Thoracic Society/European Respiratory Society jointly created a Task Force on "Outcomes for COPD pharmacological trials: from lung function to biomarkers" to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations. Copyright

doi.org/10.1183/09031936.00099306, hdl.handle.net/1765/30024
The European Respiratory Journal
Erasmus MC: University Medical Center Rotterdam

Cazzola, M., MacNee, W., Martinez, F. J., Rabe, K. F., Franciosi, L. G., Barnes, P. J., Brusasco, V., Burge, P. S., Calverley, P. M. A., Celli, B. R., Jones, P. W., Mahler, D. A., Make, B., Miravitlles, M., Page, C. P., Palange, P., Parr, D., Pistolesi, M., Rennard, S. I., … Wouters, E. (2008). Outcomes for COPD pharmacological trials: From lung function to biomarkers. In The European Respiratory Journal (Vol. 31, Number 2, pp. 416–468).https://doi.org/10.1183/09031936.00099306